BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Janus Pharmaceuticals Announces IND Filing For JA-001


10/19/2005 5:13:12 PM

LOS ANGELES--(BUSINESS WIRE)--April 4, 2005-- Cream Formulation of Anti-Zoster Drug to Be Evaluated in Phase 1 Studies in the United States Janus Pharmaceuticals Inc. (Janus) announced the filing of an Investigational New Drug application for a topical formulation of an anti-viral product with previously demonstrated activity against the varicella zoster virus (VZV) in both preclinical and clinical studies. Janus plans to conduct clinical studies evaluating the safety and efficacy of JA-001 (also known as ARYS-01 cream) a topical formulation of sorivudine for the treatment of herpes zoster infections. Sorivudine is an antiviral nucleoside analog which is transported into viral-infected cells and converted to monophosphate analogs by virus-encoded thymidine kinases. Sorivudine was originally discovered by Yamasa Corporation of Chiba, Japan, and is being developed as a topical formulation by Janus under a joint development agreement with aRigen Inc. of Tokyo, Japan. aRigen has filed several patents to cover the production method and use of the topical formulation for the treatment of herpes zoster.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES